InpharmD
YC W21Atlanta, US · Founded 2018 · 16 employees · 7 known investors
Find your way into InpharmD
1,319 people in our graph share verified history with the InpharmD team — schools, employers, funds. One of them is your warm intro.
InPharmD is a medical literature research platform that analyzes published studies to answer clinical pharmacology questions, specifically focused on adverse drug reactions and medication safety.
Founders & leadership· Y Combinator alumni (W21)
InpharmD was founded in 2018 by Ashish Advani and Tulasee Rao Chintha.


Investors · 7
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$6M disclosed across 1 of 2 rounds · 2023
- Undisclosed amountSeries SeedDec 2023
645 Ventures (lead), Atlanta Ventures, Qlarant Capital, SF ELC, Y Combinator
Source ↗ - $6MraisedDec 2023 · 2 sources
645 Ventures (lead), Atlanta Ventures, Qlarant Capital, SF ELC, Y Combinator
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlapCompanies competing with InpharmD for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does InpharmD do?
- InPharmD is a medical literature research platform that analyzes published studies to answer clinical pharmacology questions, specifically focused on adverse drug reactions and medication safety.
- Who founded InpharmD?
- InpharmD was founded by Ashish Advani, Tulasee Rao Chintha in 2018.
- Who are InpharmD's investors?
- InpharmD's investors include 645 Ventures, Asymmetry Ventures, Atlanta Tech Village, Y Combinator.
- How much funding has InpharmD raised?
- InpharmD has disclosed $6M raised across 1 of its 2 known rounds.
- Where is InpharmD headquartered?
- InpharmD is headquartered in Atlanta, US.




